MedTrace Logo

Effect of Inhaled Pre-prandial Human Insulin on Blood Glucose Control in Type 2 Diabetes

NCT00427154 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 227

Last updated 2018-09-05

No results posted yet for this study

Summary

This trial is conducted in the United States of America (USA). This trial will compare the changes in HbA1c after 26 weeks of inhaled insulin or rosiglitazone treatment, both in combination with metformin and glimepiride.

Conditions

Interventions

DRUG

rosiglitazone

Tablets, 4 mg once or twice daily.

DRUG

inhaled human insulin

Treat-to-target dose titration scheme, inhalation.

DRUG

metformin

Tablets, 2000 mg/day.

DRUG

glimepiride

Tablets, 8 mg/day.

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-10
Primary Completion
2008-03-11
Completion
2008-03-11

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00427154 on ClinicalTrials.gov